Patents Assigned to Integrated DNA Technologies, Inc.
-
sp. CAS12A mutants with enhanced cleavage activity at non-canonical TTTT protospacer adjacent motifs
Patent number: 11965185Abstract: Described herein are CAS12A mutants from Lachnospiraceae bacterium and methods for use thereof. These mutants have enhanced DNA cleavage activities at non-canonical TTTT protospacer adjacent motifs (PAM) compared to the wild-type enzyme.Type: GrantFiled: April 30, 2021Date of Patent: April 23, 2024Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Liyang Zhang, Christopher Anthony Vakulskas -
Patent number: 11926866Abstract: Methods for detecting on-target and predicted off-target genome editing events by providing a multiplex PCR reaction mixture with an on-target oligonucleotide primer and one or more off-target oligonucleotide primers and then hybridizing the on-target oligonucleotide primer and the one or more off-target oligonucleotide primers to target nucleic acid sequences, followed by cleaving blocking groups from the primers and extending the primers.Type: GrantFiled: January 4, 2021Date of Patent: March 12, 2024Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Joseph Dobosy, Caifu Chen, Mark Aaron Behlke, Garrett Richard Rettig
-
Patent number: 11913014Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: GrantFiled: February 7, 2022Date of Patent: February 27, 2024Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Patent number: 11788947Abstract: Systems and methods for controlling volumes of droplets is provided herein. In some cases, the systems comprise: a plurality of first light sources, a second light source, wherein a first light beam emitted a first light source of said plurality of first light sources is configured to intersect with a second light beam emitted from said second light source at an intersection area, wherein said system is configured to measure a characteristic of said droplet as it passes through said intersection area. Systems and methods for measuring volumes of droplets and for distinguishing between bubbles and droplets are also provided.Type: GrantFiled: January 31, 2019Date of Patent: October 17, 2023Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Keith Miller Anderson, Guillermo Alfredo Cornejo
-
Publication number: 20230257805Abstract: The present disclosure provides methods and kits for ligation-coupled PCR. Methods for performing ligation and PCR and, optionally, enzymatic digestion in a single closed tube are provided. Methods and kits for splint-mediated primer assembly and ligation-coupled PCR are also provided.Type: ApplicationFiled: November 14, 2022Publication date: August 17, 2023Applicant: Integrated DNA Technologies, Inc.Inventors: Vladimir Makarov, Jordan Rosefigura, Bita Lahann, Robert D. Stedtfeld
-
Patent number: 11724261Abstract: A synthesizer system includes a vacuum block, a sealing plate coupled to the vacuum block, a synthesis plate having a plurality of wells, and an inflatable seal coupled to both the sealing plate and the synthesis plate and forming a seal between the sealing plate and the synthesis plate.Type: GrantFiled: May 12, 2020Date of Patent: August 15, 2023Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Robert West, Gregory Hodges, Justin Kline, Scott Steburg
-
Patent number: 11697836Abstract: A bottleneck in the Next Generation Sequencing (NGS) workflow is the quantification of libraries for accurate pooling and loading of the sequencing instrument flow cell or chip. Disclosed herein are methods that improve performance and reduce time compared to existing methods.Type: GrantFiled: March 26, 2021Date of Patent: July 11, 2023Assignee: Integrated DNA Technologies, Inc.Inventors: Vladimir Makarov, Sergey Chupreta
-
Patent number: 11692219Abstract: The invention pertains to construction of next-generation DNA sequencing (NGS) libraries for whole genome sequencing, targeted resequencing, sequencing-based screening assays, metagenomics, or any other application requiring sample preparation for NGS.Type: GrantFiled: January 5, 2021Date of Patent: July 4, 2023Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Zachary Zwirko, Yu Zheng, Mirna Jarosz, Caifu Chen, Joseph Walder
-
Patent number: 11566282Abstract: The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.Type: GrantFiled: October 15, 2016Date of Patent: January 31, 2023Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Mark Aaron Behlke, John Robert Havens, Mirna Jarosz, Zachary Zwirko, Doron Lipson, Frank Soo Juhn
-
Patent number: 11566283Abstract: The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.Type: GrantFiled: October 15, 2016Date of Patent: January 31, 2023Assignee: Integrated DNA Technologies, Inc.Inventors: Mark Aaron Behlke, John Robert Havens
-
Patent number: 11459559Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system.Type: GrantFiled: October 21, 2016Date of Patent: October 4, 2022Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
-
Patent number: 11447758Abstract: The present disclosure concerns polynucleotides and amino acids of Acidaminococcus sp. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.Type: GrantFiled: August 8, 2019Date of Patent: September 20, 2022Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Liyang Zhang, Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Kristin Renee Beltz, Mark Aaron Behlke
-
Patent number: 11427818Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: GrantFiled: July 17, 2020Date of Patent: August 30, 2022Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Patent number: 11308055Abstract: Disclosed herein are nucleic acid-based data storage systems and nucleic acid data storage constructs comprising reusable nucleic acid sequences, each representing information carried by a single bit (and, in some embodiments, one or more adjacent bits) within a bit string, and each furthermore representing the position of the single bit within the bit string. Also described are methods for storing data in the nucleic acid-based data storage systems and nucleic acid data storage constructs of the disclosure.Type: GrantFiled: November 17, 2020Date of Patent: April 19, 2022Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Joseph Alan Walder, Jeffrey A. Manthey, William E. Martin, III, Shawn Allen
-
Patent number: 11293022Abstract: This invention pertains to single-stranded carrier nucleic acids and their methods of use for enhancing genome editing ribonucleoprotein complex transfection into cells and the resulting enhancement of CRISPR editing on the target DNA within those cells, as well as introduction of chemical modifications which reduce the integration of the single-stranded carrier nucleic acids at double-stranded breaks.Type: GrantFiled: December 12, 2017Date of Patent: April 5, 2022Assignee: Integrated DNA Technologies, Inc.Inventors: Rolf Turk, Mark A. Behlke, Chris Vinci
-
Patent number: 11242542Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRISPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: GrantFiled: April 26, 2018Date of Patent: February 8, 2022Assignee: Integrated DNA Technologies, Inc.Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Patent number: 11136567Abstract: This invention pertains to recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR/Cpf1 endonuclease systems and mammalian cell lines encoding recombinant AsCpf1 or LbCpf1 polypeptides. The invention includes recombinant ribonucleoprotein complexes and CRSPR/Cpf1 endonuclease systems having a suitable AsCpf1 crRNA is selected from a length-truncated AsCpf1 crRNA, a chemically-modified AsCpf1 crRNA, or an AsCpf1 crRNA comprising both length truncations and chemical modifications. Methods of performing gene editing using these systems and reagents are also provided.Type: GrantFiled: November 22, 2017Date of Patent: October 5, 2021Assignee: Integrated DNA Technologies, Inc.Inventors: Mark Aaron Behlke, Michael Allen Collingwood, Rolf Turk, Christopher Anthony Vakulskas
-
Patent number: 11053537Abstract: The invention pertains to construction of next-generation DNA sequencing (NGS) libraries for whole genome sequencing, targeted resequencing, sequencing-based screening assays, metagenomics, or any other application requiring sample preparation for NGS.Type: GrantFiled: May 25, 2018Date of Patent: July 6, 2021Assignee: Integrated DNA Technologies, Inc.Inventors: Mirna Jarosz, Madelyn Light, Jiashi Wang, Kristina Giorda
-
Patent number: 11034989Abstract: The invention provides methods for the synthesis of long oligonucleotides, genes and gene fragments. The methods include the manufacture of genes or gene fragments that can be then inserted into a variety of vectors.Type: GrantFiled: May 10, 2017Date of Patent: June 15, 2021Assignee: Integrated DNA Technologies, Inc.Inventors: Shawn Allen, Stephen Gunstream, Scott Rose
-
Patent number: 10982247Abstract: This invention relates to mutant DNA polymerases having an enhanced template discrimination activity compared with the corresponding unmodified DNA polymerase counterparts, wherein the amino acid sequence of the mutant DNA polymerase includes at least one substitution at residue positions structurally and functionally homologous or orthologous positions 783 or 784 of an unmodified Taq DNA polymerase.Type: GrantFiled: December 21, 2016Date of Patent: April 20, 2021Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Mark Aaron Behlke, Joseph A. Walder, Richard Owczarzy, Scott D. Rose, Joseph R. Dobosy, Susan M. Rupp